4045 Background: FOLFOX plus nivolumab (nivo) has become standard of care for first-line therapy of patients (pts) with esophagogastric adenocarcinomas. FL... S Lorenzen,T Goetze,R Hofheinz,... - 《Journal of Clinical Oncology》 被引量: 0发表: 2023年 196PThe tolerability and efficacy of...
Nivolumab (NIVO) plus chemotherapy (chemo) or ipilimumab (ipi) vs chemo as first-line (1L) treatment for advanced gastric cancer/gastroesophageal junction cancer/esophageal adenocarcinoma (GC/GEJC/EAC): CheckMate 649 study. Abstract. Ann Oncol. 2021;32(suppl 5):S1329-S1330. doi:10.1016/j....
had synergistic or additive effects, as well as good safety with out overlapping major adverse events.20 Combination ther apy achieved good efficacy and survival benefit in several solid tumors such as advanced non-small-cell lung cancer (NSCLC), gastric cancer, and esophageal cancer. Howev...
4045 Background: FOLFOX plus nivolumab (nivo) has become standard of care for first-line therapy of patients (pts) with esophagogastric adenocarcinomas. FL... S Lorenzen,T Goetze,R Hofheinz,... - 《Journal of Clinical Oncology》 被引量: 0发表: 2023年 196PThe tolerability and efficacy of...
4045 Background: FOLFOX plus nivolumab (nivo) has become standard of care for first-line therapy of patients (pts) with esophagogastric adenocarcinomas. FL... S Lorenzen,T Goetze,R Hofheinz,... - 《Journal of Clinical Oncology》 被引量: 0发表: 2023年 196PThe tolerability and efficacy of...
4045 Background: FOLFOX plus nivolumab (nivo) has become standard of care for first-line therapy of patients (pts) with esophagogastric adenocarcinomas. FL... S Lorenzen,T Goetze,R Hofheinz,... - 《Journal of Clinical Oncology》 被引量: 0发表: 2023年 196PThe tolerability and efficacy of...
had synergistic or additive effects, as well as good safety with out overlapping major adverse events.20 Combination ther apy achieved good efficacy and survival benefit in several solid tumors such as advanced non-small-cell lung cancer (NSCLC), gastric cancer, and esophageal cancer. Howev...